Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis

被引:170
作者
Ciurea, Stefan O.
Merchant, Delwin
Mahmud, Nadim
Ishii, Takefumi
Zhao, Yan
Hu, Wenyang
Bruno, Edward
Barosi, Giovanni
Xu, Mingjiang
Hoffman, Ronald
机构
[1] Univ Illinois, Coll Med Chicago, COMRB, Hematol Oncol Sect,Dept Med, Chicago, IL 60612 USA
[2] Policlin San Matteo, IRCCS, I-27100 Pavia, Italy
[3] Myeloproliferat Dis Res Consortium, New York, NY USA
关键词
D O I
10.1182/blood-2006-12-064626
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to investigate the biologic processes underlying and resulting from the megalkaryocytic hyperplasia that characterizes idiopathic myelofibrosis (IMF), peripheral blood CD34(+) cells isolated from patients with IMF, polycythemia vera (PV), and G-CSF-mobilized healthy volunteers were cultured in the presence of stem cell factor and thrombopoietin. IMF CD34(+) cells generated 24-fold greater numbers of megakaryocytes (MKs) than normal CD34(+) cells. IMF MKs were also shown to have a delayed pattern of apoptosis and to overexpress the antiapoptotic protein bcl-xL. MK hyperplasia in IMF is, therefore, likely a consequence of both the increased ability of IMF progenitor cells to generate MKs and a decreased rate of MK apoptosis. Media conditioned (CM) by CD61(+) cells generated in vitro from CD34(+) cells were then assayed for the levels of growth factors and proteases. Higher levels of transforming growth factor-beta (TGF-beta) and active matrix metalloprotein-ase-9 (MMP9) were observed in media conditioned with IMF CD61(+) cells than normal or PV CD61(+) cells. Both normal and IMF CD61(+) cells produced similar levels of VEGF. MK-derived TGF-B and MMP-9, therefore, likely contribute to the development of many pathological epiphenomena associated with IMF.
引用
收藏
页码:986 / 993
页数:8
相关论文
共 42 条
  • [31] MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
    Pardanani, Animesh D.
    Levine, Ross L.
    Lasho, Terra
    Pikman, Yana
    Mesa, Ruben A.
    Wadleigh, Martha
    Steensma, David P.
    Elliott, Michelle A.
    Wolanskyj, Alexandra R.
    Hogan, William J.
    McClure, Rebecca F.
    Litzow, Mark R.
    Gilliland, D. Gary
    Tefferi, Ayalew
    [J]. BLOOD, 2006, 108 (10) : 3472 - 3476
  • [32] MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
    Pikman, Yana
    Lee, Benjamin H.
    Mercher, Thomas
    McDowell, Elizabeth
    Ebert, Benjamin L.
    Gozo, Maricel
    Cuker, Adam
    Wernig, Gerlinde
    Moore, Sandra
    Galinsky, Ilene
    DeAngelo, Daniel J.
    Clark, Jennifer J.
    Lee, Stephanie J.
    Golub, Todd R.
    Wadleigh, Martha
    Gilliland, D. Gary
    Levine, Ross L.
    [J]. PLOS MEDICINE, 2006, 3 (07): : 1140 - 1151
  • [33] RAMESHWAR P, 1994, J IMMUNOL, V153, P2819
  • [34] Allogeneic hematopoietic stern-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia
    Rondelli, D
    Barosi, G
    Bacigalupo, A
    Prchal, JT
    Popat, U
    Alessandrino, EP
    Spivak, JL
    Smith, BD
    Klingemann, HG
    Fruchtman, S
    Hoffman, R
    [J]. BLOOD, 2005, 105 (10) : 4115 - 4119
  • [35] ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells
    Safina, A.
    Vandette, E.
    Bakin, A. V.
    [J]. ONCOGENE, 2007, 26 (17) : 2407 - 2422
  • [36] Antiapoptotic protein Bcl-xL is up-regulated during megakaryocytic differentiation of CD34+ progenitors but is absent from senescent megakaryocytes
    Sanz, C
    Benet, L
    Richard, C
    Badia, B
    Andreu, EJ
    Prosper, F
    Fernández-Luna, JL
    [J]. EXPERIMENTAL HEMATOLOGY, 2001, 29 (06) : 728 - 735
  • [37] Expression of Bcl-x in erythroid precursors from patients with polycythemia vera
    Silva, M
    Richard, C
    Benito, A
    Sanz, C
    Olalla, I
    Fernández-Luna, JL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (09) : 564 - 571
  • [38] Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells
    Tenedini, E
    Fagioli, ME
    Vianelli, N
    Tazzari, PL
    Ricci, F
    Tagliafico, E
    Ricci, P
    Gugliotta, L
    Martinelli, G
    Tura, S
    Baccarani, M
    Ferrari, S
    Catani, L
    [J]. BLOOD, 2004, 104 (10) : 3126 - 3135
  • [39] TEOFILI L, 2007, BLOOD
  • [40] Terui Y, 1998, EXP HEMATOL, V26, P236